<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129479</url>
  </required_header>
  <id_info>
    <org_study_id>GAL-EMR-4008</org_study_id>
    <nct_id>NCT01129479</nct_id>
  </id_info>
  <brief_title>Galantamine Treatment for Nonfluent Aphasia in Stroke Patients</brief_title>
  <official_title>Galantamine Treatment for Nonfluent Aphasia in Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho-McNeil Neurologics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive impairment after stroke is common and has a major effect on morbidity and quality&#xD;
      of life. Acetylcholinesterase inhibitors have demonstrated benefit in vascular dementia, but&#xD;
      efficacy in treating more circumscribed cognitive deficits following stroke, such as aphasia,&#xD;
      has not been systematically investigated.&#xD;
&#xD;
      This study evaluated the efficacy of Galantamine (Reminyl) in subjects with chronic, stable&#xD;
      non-fluent aphasia secondary to stroke. Subjects enrolled in a double-blind placebo-&#xD;
      controlled cross-over study that employed a comprehensive battery of language tests and&#xD;
      measures of general cognitive and behavioral status that will be used to control for factors&#xD;
      that may influence language functioning. The primary study outcome was a within-subject&#xD;
      comparison of changes in language function and behavioral scores between placebo and&#xD;
      active-treatment phases (12 weeks each). Our hypothesis was that by increasing acetylcholine&#xD;
      levels, and facilitating activity of other neurotransmitters affecting attentional systems,&#xD;
      Galantamine would produce gains in both language and behavioral scores in patients suffering&#xD;
      chronic effects in cognitive systems due to injury following stroke.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spontaneous Speech</measure>
    <time_frame>Every 4 weeks</time_frame>
    <description>Analysis of spontaneous speech production with picture description (cookie theft picture): content units and lexical efficiency; as well as Boston Naming Test naming latency.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADP</measure>
    <time_frame>Every 4 weeks</time_frame>
    <description>Aphasia Diagnostic Profile: lexical Retrieval, phrase length, phonemic fluency, and category fluency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Communication Log scores</measure>
    <time_frame>Every 12 weeks</time_frame>
    <description>Subject communication change log scores Caregiver communication change log score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Aphasia</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Galantamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galantamine</intervention_name>
    <description>Galantamine XL 8 mg for 4 weeks, followed by Galantamine XL 16 mg for subsequent 12 weeks. Taken in the morning with food for total of 12 weeks.</description>
    <arm_group_label>Galantamine</arm_group_label>
    <other_name>Razadyne</other_name>
    <other_name>Reminyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <description>Placebo pill each morning with food for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of aphasia with relatively spared comprehension.&#xD;
&#xD;
          -  Onset 6 months or greater prior to enrollment.&#xD;
&#xD;
          -  Native English speaker&#xD;
&#xD;
          -  Right-handed.&#xD;
&#xD;
          -  Adults (18 years of age or older).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving ongoing individual speech therapy. (Most patients are no longer&#xD;
             eligible for individualized speech therapy after 6 months from stroke onset, thus this&#xD;
             should not eliminate many patients).&#xD;
&#xD;
          -  Extremely mild or extremely severe aphasia. (Boston Naming Test Score &lt;3 or &gt;45 items&#xD;
             named from 60 items).&#xD;
&#xD;
          -  Global dementia (and any other patient with reduced decisional capacity requiring a&#xD;
             legally authorized representative for consent).&#xD;
&#xD;
          -  Presence of major cognitive deficit other than aphasia caused by stroke related&#xD;
             disease.&#xD;
&#xD;
          -  Contraindications to cholinomimetic agents: History of active peptic ulcer disease&#xD;
             within 1 year, Severe asthma, unstable angina, bradyarrhythmia with resting pulse less&#xD;
             than 50, sick sinus syndrome, or seizures.&#xD;
&#xD;
          -  Major psychiatric disorders that affect cognition including: psychosis, major&#xD;
             depression, bipolar disorder, alcohol or substance abuse.&#xD;
&#xD;
          -  Major medical conditions that alter cognition (e.g., heart failure, dialysis dependent&#xD;
             renal failure, hepatic failure, active cancer).&#xD;
&#xD;
          -  Impairments that affect metabolism of the medication including: Severe renal&#xD;
             impairment (Creatinine clearance equal to or greater than 9), and moderate or severe&#xD;
             hepatic impairment (Child-Pugh score &gt;7)&#xD;
&#xD;
          -  Patients using medications that have major effects on brain neurotransmitter systems&#xD;
             or cognition within 2 months of enrollment. Exclusionary medications are: medications&#xD;
             with significant anti-cholinergic activity (tricyclic antidepressants,&#xD;
             diphenhydramine), anti-Parkinsonian medications (including Sinemet, amantadine,&#xD;
             bromocriptine, pergolide, selegiline), and narcotic analgesics (&gt; 2 doses per week).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heidi L Roth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <last_update_submitted>May 21, 2010</last_update_submitted>
  <last_update_submitted_qc>May 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Heidi Roth</name_title>
    <organization>University of North Carolina</organization>
  </responsible_party>
  <keyword>Aphasia</keyword>
  <keyword>treatment</keyword>
  <keyword>cholinesterase inhibitor</keyword>
  <keyword>stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Aphasia</mesh_term>
    <mesh_term>Aphasia, Broca</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Galantamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

